2026-01-18 - Analysis Report
**Financial Report: Johnson & Johnson (JNJ)**

### Company Overview
Johnson & Johnson is a multinational health care company that develops medical devices, pharmaceuticals, and consumer packaged goods.

### Return Rate Comparison

* Cumulative return of review stock (JNJ): 60.63%
* Cumulative return of comparison stock (S&P 500, VOO): 93.36%
* Degree of divergence: -32.70

### Alpha, Beta Analysis

| Year     | CAGR | MDD  | Alpha | Beta | Cap(B) |
|----------|------|------|-------|------|--------|
| 2016-2018 | 6.0% | 16.8% | 3.0% | 0.7 | 310.9B |
| 2017-2019 | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020 | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021 | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022 | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023 | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024 | -30.0% | 13.8% | -50.0% | 0.2 | 348.4B |
| 2023-2025 | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

### Recent Stock Price Fluctuations

* 5-day SMA: $216.03
* 20-day SMA: $208.94
* 60-day SMA: $201.95

### RSI, PPO Index Indicators

* Market Risk Indicator (MRI): 0.80
* RSI: 70.76
* PPO: 0.54
* Hybrid Signal: Buy (Cash 0%)
* Recent (20 days) relative divergence change: +14.60 (improving)
* 7-day Rank change: -52 (rank down)
* 7-day Dynamic Expected Return change: +36.50 (improving)
* Expected Return (%): -38.40%

### Recent News & Significant Events

* [2026-01-13] Hereâ€™s What Lifted Johnson & Johnson (JNJ) in Q4 - Yahoo Finance
* [2026-01-16] Johnson & Johnson Stock Capital Return Hits $159 Bil - Trefis
* [2026-01-14] Johnson & Johnson (NYSE:JNJ) Stock Price Up 2.3% - Here's Why - MarketBeat
* [2026-01-13] Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court - Reuters
* [2026-01-03] 2 Healthcare Stocks to Buy in a Bear Market - The Motley Fool

### Analyst Opinions

Analyst Consensus:
* Key: Buy
* Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
* Opinions: 24
* Target Price (avg/high/low): 212.00 / 240.00 / 155.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3 | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |

### Financial Information: Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

### Financial Information: Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

### Comprehensive Analysis

Johnson & Johnson had a lower return rate compared to the S&P 500, with a cumulative return of 60.63% versus 93.36%. The company's Alpha, Beta analysis shows a relatively stable performance, with a mean CAGR of 15.8% and a mean Beta of 0.6. The recent stock price fluctuations showed a decrease in the 5-day SMA, 20-day SMA, and 60-day SMA. The RSI and PPO indicators suggest a neutral market risk indicator, but with a recent improvement in relative divergence change. The expected return is -38.40%. The recent news and significant events suggest a possible upswing in the company's stock price. The analyst consensus is buy, with a mean target price of 212.00. The recent earnings analysis showed a decrease in revenue and EPS. The financial information reveals a stable revenue and profitability, but with a decrease in equity and ROE.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.